Piper Sandler: Teva Pharmaceutical Indus (TEVA.US) rating was confirmed, adjusted from an increase to an increase rating, and the target price was adjusted from $19.00 to $20.00.
Piper Sandler：重申Teva Pharmaceutical Indus(TEVA.US)评级，由增持调整至增持评级, 目标价由19.00美元调整至20.00美元。
Piper Sandler: Teva Pharmaceutical Indus (TEVA.US) rating was confirmed, adjusted from an increase to an increase rating, and the target price was adjusted from $19.00 to $20.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.